| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.055 | 0.3 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.023 | 0.6 |